<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391391</url>
  </required_header>
  <id_info>
    <org_study_id>FID07</org_study_id>
    <nct_id>NCT00391391</nct_id>
  </id_info>
  <brief_title>Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children</brief_title>
  <official_title>Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route in Comparison With Intramuscular Vaccination With Standard Fluzone® in Healthy Infants and Young Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine
      to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.

      Secondary Objectives:

        -  To describe the immunogenicity of of Investigational Fluzone vaccine to the standard
           Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.

        -  To describe the safety of of Investigational Fluzone vaccine to the standard Fluzone®
           vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) Before and Post Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
    <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Achieved A 4-Fold Rise in Serum HAI Antibody Titer Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Achieved Seroprotection Before and Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroprotection was defined as participants achieving a post-dose antibody titers ≥40.
Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Achieved Seroconversion Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Seroconversion was defined as the conversion to a post-vaccination titer of ≥ 40 for subjects with pre-vaccination titer &lt; 10, or at least a 4-fold increase in post vaccination titer for subjects with pre vaccination titer ≥ 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 6 to 35 Months.</measure>
    <time_frame>Day 0 to Day 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Tenderness, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of Appetite, and Irritability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 3 to 8 Year Olds</measure>
    <time_frame>Day 0 to Day 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">520</enrollment>
  <condition>Orthomyxoviridae Infection</condition>
  <condition>Influenza</condition>
  <condition>Myxovirus Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Split, Inactivated, Trivalent Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Split, Inactivated, Trivalent Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Split, Inactivated, Trivalent Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Split, Inactivated, Trivalent Influenza Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine</intervention_name>
    <description>Vaccine (infant dose)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine</intervention_name>
    <description>Vaccine (children dose)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)</intervention_name>
    <description>Vaccine (infant dose)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Fluzone® 2006/2007 Formulation.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)</intervention_name>
    <description>Vaccine (children dose)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Fluzone® 2006/2007 Formulation.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  Aged 6 months to 8 years but not yet 9 years on the day of inclusion.

          -  Subject is healthy, as determined by medical history.

          -  Institution Review Board (IRB)-approved informed assent form signed by eligible
             subject (if required by local regulations) and/or an IRB-approved informed consent
             form signed by the subject's parent(s) or legal representative (and by an independent
             witness if required by local regulations).

          -  Parent or legal guardian willing and able to attend (bring subject) to all scheduled
             visits and comply with all trial procedures.

        Exclusion Criteria :

          -  Participation in another clinical trial in the 4 weeks preceding the trial
             vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Personal or family history of Guillain-Barré Syndrome.

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer
             chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic
             corticosteroid therapy injected or oral corticosteroids or other immunomodulator
             therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule
             of oral steroids lasting &lt; 7 days may be included in the trial as long as they have
             not received more than one course within the last two weeks prior to enrollment.

          -  Systemic hypersensitivity to eggs, chicken proteins, or any of the vaccine components,
             or a vaccine containing the same substances.

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Received blood or blood-derived products in the previous 3 months.

          -  Any vaccination in the 4 weeks preceding or following the trial vaccinations (Subjects
             can take standard childhood vaccination(s) following Visit 3 blood draw).

          -  Known current human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C
             infection or seropositivity.

          -  Known thrombocytopenia or bleeding disorder contraindicating IM vaccination.

          -  Acute medical illness, with or without fever, within the last 72 hours or an oral
             temperature ≥ 37.5 °C (99.5 °F) or rectal temperature of ≥ 38°C (100.4 °F) at the time
             of enrollment.

          -  History of seizures.

          -  Received antibiotics therapy within 72 hours preceding the trial vaccination.

          -  Received any allergy shots in the 7-day period preceding trial vaccination and/or
             scheduled to receive any allergy shots in the 7-day period after trial vaccination.

          -  Any condition, which in the opinion of the investigator would pose a health risk to
             the participant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Harrisburg</city>
        <state>Arkansas</state>
        <zip>72432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trumann</city>
        <state>Arkansas</state>
        <zip>72472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downey</city>
        <state>California</state>
        <zip>90241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <zip>71111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brainerd</city>
        <state>Minnesota</state>
        <zip>56401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2006</study_first_submitted>
  <study_first_submitted_qc>October 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2006</study_first_posted>
  <results_first_submitted>October 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 22, 2011</results_first_posted>
  <disposition_first_submitted>March 30, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>March 31, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2010</disposition_first_posted>
  <last_update_submitted>November 21, 2011</last_update_submitted>
  <last_update_submitted_qc>November 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Orthomyxoviruses</keyword>
  <keyword>Inactivated Split-virion influenza vaccine</keyword>
  <keyword>Infants</keyword>
  <keyword>children.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Orthomyxoviridae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study participants ere enrolled from 19 October to 12 December 2006 in 20 clinical centers in the US.</recruitment_details>
      <pre_assignment_details>A total of 517 of the 520 participants who met the inclusion and exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
          <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="P2">
          <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
          <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
          <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
          <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98">1 participant was not vaccinated.</participants>
                <participants group_id="P2" count="97"/>
                <participants group_id="P3" count="161">1 participant was not vaccinated.</participants>
                <participants group_id="P4" count="164">1 participant was not vaccinated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
          <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="B2">
          <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
          <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
          <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
          <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="97"/>
            <count group_id="B3" value="160"/>
            <count group_id="B4" value="163"/>
            <count group_id="B5" value="517"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.6" spread="7.51"/>
                    <measurement group_id="B2" value="21.8" spread="8.03"/>
                    <measurement group_id="B3" value="69.6" spread="22.2"/>
                    <measurement group_id="B4" value="70.8" spread="21.6"/>
                    <measurement group_id="B5" value="46.5" spread="14.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="160"/>
                    <measurement group_id="B4" value="163"/>
                    <measurement group_id="B5" value="517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) Before and Post Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
        <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
        <time_frame>Day 0 and Day 28 post-vaccination</time_frame>
        <population>Geometric Mean Titers were determined in the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Before and Post Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
          <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
          <population>Geometric Mean Titers were determined in the per-protocol population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A/H1N1 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="7.1" upper_limit="11.2"/>
                    <measurement group_id="O2" value="9.6" lower_limit="7.5" upper_limit="12.3"/>
                    <measurement group_id="O3" value="20.5" lower_limit="15.6" upper_limit="26.9"/>
                    <measurement group_id="O4" value="26.9" lower_limit="19.6" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" lower_limit="28.6" upper_limit="119.4"/>
                    <measurement group_id="O2" value="113.1" lower_limit="59.9" upper_limit="213.7"/>
                    <measurement group_id="O3" value="100.1" lower_limit="55.0" upper_limit="182.1"/>
                    <measurement group_id="O4" value="264.2" lower_limit="162.8" upper_limit="428.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.3" lower_limit="105.2" upper_limit="181.8"/>
                    <measurement group_id="O2" value="160.0" lower_limit="123.7" upper_limit="206.9"/>
                    <measurement group_id="O3" value="162.9" lower_limit="128.7" upper_limit="206.3"/>
                    <measurement group_id="O4" value="390.6" lower_limit="308.2" upper_limit="495.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" lower_limit="14.0" upper_limit="35.9"/>
                    <measurement group_id="O2" value="20.9" lower_limit="13.7" upper_limit="31.9"/>
                    <measurement group_id="O3" value="222.2" lower_limit="165.4" upper_limit="298.5"/>
                    <measurement group_id="O4" value="171.0" lower_limit="121.5" upper_limit="240.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.8" lower_limit="142.9" upper_limit="817.7"/>
                    <measurement group_id="O2" value="566.9" lower_limit="304.6" upper_limit="1054.9"/>
                    <measurement group_id="O3" value="1012.5" lower_limit="666.9" upper_limit="1537.2"/>
                    <measurement group_id="O4" value="1256.9" lower_limit="898.2" upper_limit="1758.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614.8" lower_limit="471.3" upper_limit="802.0"/>
                    <measurement group_id="O2" value="471.4" lower_limit="368.0" upper_limit="603.7"/>
                    <measurement group_id="O3" value="1111.0" lower_limit="944.0" upper_limit="1307.5"/>
                    <measurement group_id="O4" value="1344.4" lower_limit="1146.1" upper_limit="1577.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3" lower_limit="4.9" upper_limit="5.8"/>
                    <measurement group_id="O2" value="5.4" lower_limit="5.0" upper_limit="5.9"/>
                    <measurement group_id="O3" value="8.3" lower_limit="7.1" upper_limit="9.7"/>
                    <measurement group_id="O4" value="6.8" lower_limit="6.0" upper_limit="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="4.4" upper_limit="12.5"/>
                    <measurement group_id="O2" value="9.7" lower_limit="4.2" upper_limit="22.1"/>
                    <measurement group_id="O3" value="46.6" lower_limit="23.3" upper_limit="93.3"/>
                    <measurement group_id="O4" value="28.8" lower_limit="16.0" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" lower_limit="23.7" upper_limit="40.8"/>
                    <measurement group_id="O2" value="18.2" lower_limit="13.9" upper_limit="24.0"/>
                    <measurement group_id="O3" value="56.4" lower_limit="43.8" upper_limit="72.7"/>
                    <measurement group_id="O4" value="51.6" lower_limit="40.8" upper_limit="65.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Achieved A 4-Fold Rise in Serum HAI Antibody Titer Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
        <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>4-Fold Rise in Serum HAI Antibody Titers were determined in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Achieved A 4-Fold Rise in Serum HAI Antibody Titer Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
          <description>Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
          <population>4-Fold Rise in Serum HAI Antibody Titers were determined in the per-protocol population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="74" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="88" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="78" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="80" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="44" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="63" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="91" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="62" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="44" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="55" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Achieved Seroprotection Before and Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
        <description>Seroprotection was defined as participants achieving a post-dose antibody titers ≥40.
Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroprotection to vaccine antigens were determined in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Achieved Seroprotection Before and Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
          <description>Seroprotection was defined as participants achieving a post-dose antibody titers ≥40.
Antibody titers against each strain of influenza hemagglutinin were measured in the sera using the hemagglutination inhibition (HI) technique.</description>
          <population>Seroprotection to vaccine antigens were determined in the per-protocol population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="115"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A/H1N1 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="33" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="79" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="95" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="93" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="92" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="99" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="86" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="80" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="95" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="97" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="100" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="99" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="100" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Pre-vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="9" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="47" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="42" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="63" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="58" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Achieved Seroconversion Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
        <description>Seroconversion was defined as the conversion to a post-vaccination titer of ≥ 40 for subjects with pre-vaccination titer &lt; 10, or at least a 4-fold increase in post vaccination titer for subjects with pre vaccination titer ≥ 10.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroconversion to vaccine antigens were determined in the per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Achieved Seroconversion Post-vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine</title>
          <description>Seroconversion was defined as the conversion to a post-vaccination titer of ≥ 40 for subjects with pre-vaccination titer &lt; 10, or at least a 4-fold increase in post vaccination titer for subjects with pre vaccination titer ≥ 10.</description>
          <population>Seroconversion to vaccine antigens were determined in the per-protocol population</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="65" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="74" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H1N1 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="88" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="70" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="78" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="80" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="44" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="63" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup A/H3N2 Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="91" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="50" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="62" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="44" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="40" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serogroup B Post-vaccination 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="21" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="55" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="53" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 6 to 35 Months.</title>
        <description>Solicited injection site reactions: Tenderness, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of Appetite, and Irritability.</description>
        <time_frame>Day 0 to Day 7 post-vaccination</time_frame>
        <population>Safety parameters were determined post-vaccination in the safety, intend-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 6 to 35 Months.</title>
          <description>Solicited injection site reactions: Tenderness, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of Appetite, and Irritability.</description>
          <population>Safety parameters were determined post-vaccination in the safety, intend-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any injection site tenderness Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Reduced movement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site redness Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site swelling Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site induration Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 induration ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site ecchymosis Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection site tenderness Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Tenderness (Reduced movement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site redness Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site swelling Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site induration Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 induration ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site ecchymosis Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 ecchymosis ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever &gt; 103.1°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Vomiting Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting ≥ 6 episodes per 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Crying Abnormal Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal &gt;3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Drowsiness Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Sleeping most of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Appetite Lost Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost refuses most feeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Irritability Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability inconsolable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever &gt; 103.1°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Vomiting Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting ≥ 6 episodes per 24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Crying Abnormal Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying Abnormal &gt;3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Drowsiness Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness Sleeping most of the time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Appetite Lost Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite Lost refuses most feeds</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Irritability Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability inconsolable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 3 to 8 Year Olds</title>
        <description>Solicited injection site reactions: Pain, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
        <time_frame>Day 0 to Day 7 post-vaccination</time_frame>
        <population>Safety parameters were determined post-vaccination in the safety, intend-to-treat population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
            <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O2">
            <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
            <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
            <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
            <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting a Solicited Injection Site or Systemic Reactions After Each Vaccination With Either a Fluzone Intradermal or a Fluzone Intramuscular Vaccine - Age 3 to 8 Year Olds</title>
          <description>Solicited injection site reactions: Pain, Redness, Swelling, Induration and Ecchymosis. Solicited Systemic reaction: Fever (Temperature), Headache, Malaise, and Myalgia.</description>
          <population>Safety parameters were determined post-vaccination in the safety, intend-to-treat population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any injection site Pain Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="93"/>
                    <measurement group_id="O4" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Reduced movement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Redness Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Swelling Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Induration Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Ecchymosis Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Pruritus Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any injection site pain Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="98"/>
                    <measurement group_id="O4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain (Reduced movement)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Redness Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="94"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Swelling Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling ( ≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Induration Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Induration (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Injection site Ecchymosis Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Ecchymosis (≥ 5 cm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Pruritus Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever &gt; 102.2°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Headache Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Malaise Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Myalgia Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Fever Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever &gt; 102.2°F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Headache Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Malaise Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Solicited Myalgia Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia Prevents daily activities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from the day of vaccination to up to 6 months post-vaccination 2</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 1: Fluzone ID at Age 6 to 35 Months</title>
          <description>Participants at 6 to 35 Months of age on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="E2">
          <title>Group 2: Fluzone IM 6 to 35 Months Age Group</title>
          <description>Participants at 6 to 35 Months Age on enrollment that received Fluzone IM vaccine</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Fluzone ID at 3 to 8 Years Age</title>
          <description>Participants at Age 3 to 8 Years on enrollment that received Fluzone ID vaccine</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Fluzone IM 3 to 8 Years Age</title>
          <description>Participants at age 3 to 8 years on enrollment that received Fluzone IM vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="97"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="90" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="160"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="97"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="86"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Appetite lost</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="93"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="97"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E4" events="19" subjects_affected="16" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Injection site Tenderness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="93"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="87"/>
                <counts group_id="E3" events="98" subjects_affected="98" subjects_at_risk="137"/>
                <counts group_id="E4" events="90" subjects_affected="90" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Injection site Redness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="93"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="87"/>
                <counts group_id="E3" events="98" subjects_affected="98" subjects_at_risk="143"/>
                <counts group_id="E4" events="42" subjects_affected="42" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="88"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E3" events="61" subjects_affected="61" subjects_at_risk="137"/>
                <counts group_id="E4" events="30" subjects_affected="30" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site Induration</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="93"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E3" events="56" subjects_affected="56" subjects_at_risk="143"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Injection site Ecchymosis</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="88"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="143"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="136"/>
                <counts group_id="E4" events="30" subjects_affected="30" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="24" subjects_affected="24" subjects_at_risk="141"/>
                <counts group_id="E4" events="42" subjects_affected="42" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Croup infections</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="97"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" events="20" subjects_affected="18" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="97"/>
                <counts group_id="E2" events="27" subjects_affected="23" subjects_at_risk="97"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="97"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="97"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="93"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="93"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="141"/>
                <counts group_id="E4" events="25" subjects_affected="25" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying abnormal</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="93"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="44" subjects_affected="33" subjects_at_risk="97"/>
                <counts group_id="E2" events="39" subjects_affected="32" subjects_at_risk="97"/>
                <counts group_id="E3" events="60" subjects_affected="46" subjects_at_risk="160"/>
                <counts group_id="E4" events="55" subjects_affected="42" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E4" events="15" subjects_affected="12" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="97"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="97"/>
                <counts group_id="E3" events="30" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E4" events="26" subjects_affected="20" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E3" events="23" subjects_affected="23" subjects_at_risk="139"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

